This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (IXAMPLE2)

This study has been terminated.
(Interim analysis results showed that ixabepilone did not improve survival compared with control chemotherapies.)
Sponsor:
Information provided by (Responsible Party):
R-Pharm
ClinicalTrials.gov Identifier:
NCT00883116
First received: April 16, 2009
Last updated: January 27, 2017
Last verified: January 2017
  Purpose
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.

Condition Intervention Phase
Endometrial Cancer Drug: Ixabepilone Drug: Doxorubicin Drug: Paclitaxel Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy

Resource links provided by NLM:


Further study details as provided by R-Pharm:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Date of randomization to date of death or last date censored to up to approximately 26 months ]
    Survival was defined as the time from the date of randomization until the date of death. If the patient did not die, OS was censored on the last date he or she was known to be alive.


Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: Date of randomization to date of disease progression or death (or date of last tumor assessment for those who did not die or progress) up to approximately 22 months ]
    Progression-free survival was defined as the time from randomization to the date of documented disease progression. Patients who died without a reported prior progression were considered to have progressed on the date of their death. Those who did not progress or die were censored on the date of their last tumor assessment. Participants who did not have any on-study tumor assessments were censored on the date they were randomized. Measurable disease was present if the patient had 1 or more measurable lesions.

  • Best Overall Response Rate [ Time Frame: Date of randomization and every 6 weeks to end of treatment (9 cycles, or approximately Day 189) ]
    Best overall response rate was defined as the number of participants whose best response was either partial response (PR) or complete response (CR) divided by the number of participants in the treatment group. Overall tumor response was based on an integration of the evaluation of target, nontarget, and new lesions. CR=Disappearance of all clinical and radiologic evidence of target lesions. PR=At least 30% reduction in the sum of diameters of all target lesions; taking as reference the baseline study measurement. Changes in tumor measurements need not be confirmed by repeat measurements performed after the criteria for response were first met.

  • Number of Participants With a Serious Adverse Event (SAE), an SAE Related to Study Drug, Death as Outcome, a Peripheral Neuropathy Adverse Event (AE), a Grade 3 or Higher AE, and an AE Related to Study Drug [ Time Frame: From Day 1 (first dose) to 30 days past last dose (up to Day 219); 9 cycles, or 189 days + 30 days ]
    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related to study drug=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.


Enrollment: 551
Study Start Date: August 2009
Study Completion Date: February 2014
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ixabepilone, 40 mg/m^2, intravenously (IV)
Participants received ixabepilone, 40 mg/m^2, given IV over 3 hours every 21 days until unacceptable toxicity or disease progression
Drug: Ixabepilone
Other Names:
  • Ixempra
  • BMS-247550
Active Comparator: Control chemotherapy (Paclitaxel or Doxorubicin)
Participants received either paclitaxel, 175 mg/m^2 given IV over 3 hours, or per institutional guidelines but not exceeding 3 hours, every 21 days until disease progression or unacceptable toxicity or doxorubicin, 60 mg/m^2 given IV per institutional guidelines every 21 days, depending on the prior therapy received, until disease progression, unacceptable toxicity, or cumulative dose of 500 mg/m^2.
Drug: Doxorubicin
Other Names:
  • Adriamycin PFS/RDF
  • Adriacin
  • Adriblastina
  • Adriablastine
  • Adrimedac
  • DOXO-CELL
  • Doxolem
  • Doxorubin
  • Farmiblastina
  • Rubex
Drug: Paclitaxel
Other Names:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol Praxel
  • Taxol Konzentrat
  • F1-106

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria

  • Women aged 18 years and older
  • Histologic or cytologic diagnosis of endometrial carcinoma
  • Evidence that the cancer is advanced, recurrent, or metastatic and not curable by local measures, such as surgery or radiation.
  • Karnofsky performance status >=70
  • Measurable or nonmeasurable disease that has progressed since last treatment.

    • If only disease is confined to a solitary lesion, its neoplastic nature must be confirmed by histology or cytology.
    • Disease in a previously irradiated field is acceptable as the only site of measurable disease only if there has been clear progression since completion of radiotherapy.
  • All therapy directed at endometrial cancer must be discontinued 21 days prior to start of treatment, except for hormonal therapy which must be discontinued at least 1 week prior to start of study treatment. Concurrent administration of hormone replacement therapy is allowed.
  • Prior therapy: Participants must have failed 1 prior platinum-based chemotherapeutic regimen for endometrial cancer. May have received 2 prior chemotherapy regimens if 1 regimen was given for stage I or II disease. May have received any number of prior non-cytotoxic regimens such as monoclonal antibodies, cytokines, signal transduction inhibitors, or hormonal therapy. Previous radiation therapy is allowed.

Key Exclusion Criteria

  • Carcinosarcoma (malignant mixed mullerian tumor)
  • Endometrial leiomyosarcoma and endometrial stromal sarcomas
  • Participants who received no prior chemotherapy for endometrial cancer or ≥2 prior chemotherapy regimens (exceptions defined in protocol)
  • Known brain metastases
  • Receipt of prior ixabepilone therapy
  • Concurrent active infection requiring antibiotics or other therapy
  • Concurrent unstable disease or other debilitating illness, such as congestive heart failure, unstable angina, myocardial infarction, or other cardiac disease that could jeopardize participation, within the last 6 months
  • For participants whose prior therapy did not include an anthracycline and therefore may be randomized to doxorubicin, left ventricular ejection fraction <50% as measured by multigated radionuclide angiography or echocardiography
  • History of malignancy, except nonmelanoma skin cancer, carcinoma in situ of the cervix, or carcinoma in situ of the breast, within the last 5 years that has not been treated with chemotherapy
  • Known human immunodeficiency viral infection
  • Psychiatric disorders or other conditions rendering the participant incapable of complying with protocol requirements
  • Absolute neutrophil count <1500/mm^3
  • Platelets <100,000/mm^3
  • Hemoglobin <9 g/dL
  • Total bilirubin >1.5*upper limit of normal (ULN), except for those with Gilbert's disease
  • Aspartate aminotransferase or alanine aminotransferase >2.5*ULN
  • Serum creatinine >1.5*ULN
  • Grade ≥2 neuropathy (sensory or motor)
  • No concurrent therapy (chemotherapy, hormonal, or investigational) directed at endometrial cancer during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00883116

  Hide Study Locations
Locations
United States, Alabama
University Of South Alabama
Mobile, Alabama, United States, 36604
United States, Colorado
Rocky Mountain Gynecologic Oncology
Englewood, Colorado, United States, 80113
United States, Connecticut
Peter E. Schwartz, Md
New Haven, Connecticut, United States, 06510-3206
Hematology Oncology, P.C.
Stamford, Connecticut, United States, 06902
United States, Florida
Gynecologic Oncology Assoc.,Inc
Hollywood, Florida, United States, 33021
Florida Hospital Cancer Institute
Orlando, Florida, United States, 32804
Sarasota Memorial Health Care System
Sarasota, Florida, United States, 34239
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Georgia
Georgia Health Science University
Augusta, Georgia, United States, 30912-3335
United States, Illinois
Sudarshan K. Sharma, Md
Hinsdale, Illinois, United States, 60521
Central Dupage Hospital Cancer Center
Warrenville, Illinois, United States, 60555
United States, Indiana
St. Vincent Hospital And Health Care Center, Inc.
Indianapolis, Indiana, United States, 46260
United States, Louisiana
Hematology And Oncology Specialists, Llc
Marrero, Louisiana, United States, 70072
United States, Maryland
Women'S Health Specialists
Rockville, Maryland, United States, 20852
United States, Michigan
Sparrow Regional Cancer Center
Lansing, Michigan, United States, 48912
United States, Minnesota
University Of Minnesota
Minneapolis, Minnesota, United States, 55455-0374
United States, Mississippi
Saint Dominic's Gynecologic Oncology
Jackson, Mississippi, United States, 39216
United States, Missouri
Matthew A Powell, Md
Saint Louis, Missouri, United States, 63110
United States, North Carolina
Blumenthal Cancer Center
Charlotte, North Carolina, United States, 28204
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Oklahoma
Peggy And Charles Stephenson Oklahoma Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Tulsa Cancer Institute
Tulsa, Oklahoma, United States, 74136
United States, Pennsylvania
Pennsylvania Oncology Hematology Associates
Philadelphia, Pennsylvania, United States, 19106
Magee-Womens Hospital Of Upmc Laboratory
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
Women & Infants Hospital Of Ri
Providence, Rhode Island, United States, 02908
United States, South Carolina
Cancer Centers Of The Carolinas
Greenville, South Carolina, United States, 29615
United States, Tennessee
Tennessee Gynecologic Oncology Group, Llc
Chattanooga, Tennessee, United States, 37403
United States, Virginia
University Of Virginia
Charlottesville, Virginia, United States, 22908
Argentina
Local Institution
Rosario, Santa Fe, Argentina, S2000DSK
Local Institution
La Rioja, Argentina, 5300
Local Institution
Salta, Argentina, A4406CLA
Australia, Queensland
Local Institution
Milton, Queensland, Australia, 4064
Australia, Victoria
Local Institution
East Bentleigh, Victoria, Australia, 3165
Belgium
Local Institution
Gent, Belgium, 9000
Local Institution
Leuven, Belgium, B-3000
Brazil
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000
Local Institution
Barretos, Sao Paulo, Brazil, 14784-400
Local Institution
Jau, Sao Paulo, Brazil, 17210-120
Local Institution
Sao Paulo, Brazil, 01246-000
Canada, Alberta
Local Institution
Calgary, Alberta, Canada, T2N 4N2
Canada, British Columbia
Local Institution
Surrey, British Columbia, Canada, V3V 1Z2
Local Institution
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Nova Scotia
Local Institution
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Local Institution
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Local Institution
Fleurimont, Quebec, Canada, J1H 5N4
Local Institution
Montreal, Quebec, Canada, H2L 4M1
Czech Republic
Local Institution
Brno, Czech Republic, 656 53
Local Institution
Hradec Kralove, Czech Republic, 500 05
Denmark
Local Institution
Copenhagen, Denmark, 2100
Local Institution
Herlev, Denmark, 2730
Local Institution
Odense C, Denmark, 5000
France
Local Institution
Paris, France, 75004
Local Institution
Poitiers, France, 86000
Local Institution
Saint Herblain Cedex, France, 44805
Local Institution
Villejuif Cedex, France, 94800
Greece
Local Institution
Athens, Greece, 11528
Hungary
Local Institution
Budapest, Hungary, 1122
Local Institution
Miskolc, Hungary, H-3526
Italy
Local Institution
Brescia, Italy, 25123
Local Institution
Campobasso, Italy, 86100
Local Institution
Meldola (fc), Italy, 47014
Local Institution
Milano, Italy, 20141
Local Institution
Monza, Italy, 20052
Local Institution
Roma, Italy, 00168
Mexico
Local Institution
Df, Distrito Federal, Mexico, 06720
Local Institution
Mexico City, Distrito Federal, Mexico, 06726
Local Institution
Mexico, Distrito Federal, Mexico, 07760
Local Institution
Monterrey, Distrito Federal, Mexico, 64320
Local Institution
Tlalpan, Distrito Federal, Mexico, 14080
Local Institution
Guadalajara, Jalisco, Mexico, 44340
Norway
Local Institution
Bergen, Norway, 5021
Local Institution
Oslo, Norway, 0310
Peru
Local Institution
Lima, Peru, 34
Local Institution
Lima, Peru, Lima 11
Local Institution
Lima, Peru, LIMA 13
Russian Federation
Local Institution
Ivanovo, Russian Federation, 153013
Local Institution
Moscow, Russian Federation, 115 478
Local Institution
Moscow, Russian Federation, 117997
Local Institution
Obninsk, Russian Federation, 249036
Local Institution
St Pertersburg, Russian Federation, 198255
Local Institution
St Petersburg, Russian Federation, 197758
Spain
Local Institution
Barcelona, Spain, 08035
Local Institution
Madrid, Spain, 28040
Local Institution
Valencia, Spain, 46009
Sweden
Local Institution
Goteborg, Sweden, 413 45
Local Institution
Linkoping, Sweden, 581 85
Local Institution
Stockholm, Sweden, 171 76
Local Institution
Umea, Sweden, 901 85
Local Institution
Uppsala, Sweden, 751 85
United Kingdom
Local Institution
Bristol, Avon, United Kingdom, BS2 8ED
Local Institution
Glasgow, Dumfries & Galloway, United Kingdom, G12 0YN
Local Institution
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
Local Institution
Leeds, Yorkshire, United Kingdom, LS9 7TF
Sponsors and Collaborators
R-Pharm
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: R-Pharm
ClinicalTrials.gov Identifier: NCT00883116     History of Changes
Other Study ID Numbers: CA163-196
2008-007167-16
Study First Received: April 16, 2009
Results First Received: December 6, 2013
Last Updated: January 27, 2017

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female
Doxorubicin
Liposomal doxorubicin
Paclitaxel
Albumin-Bound Paclitaxel
Epothilones
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators

ClinicalTrials.gov processed this record on June 26, 2017